Brokerages Set Bruker Corporation (NASDAQ:BRKR) Price Target at $51.30

Key Points

• Bruker Corporation has received an average recommendation of "Hold" from eleven research firms, with six ratings for hold and five for buy, and a 12-month price objective of $51.30.
• CEO Frank H. Laukien purchased 2,608 shares of Bruker stock at $38.36 per share, increasing his ownership to approximately 38.46 million shares valued at nearly $1.48 billion.
• Bruker recently reported Q2 earnings of $0.32 EPS, missing estimates, with revenue of $797.4 million, and has announced a quarterly dividend of $0.05 per share.

Shares of Bruker Corporation (NASDAQ:BRKR - Get Free Report) have been given a consensus rating of "Hold" by the eleven research firms that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $51.30.

Several equities research analysts have recently commented on the company. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the stock a "hold" rating in a research note on Tuesday, August 5th. Citigroup reduced their price objective on Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research note on Monday, August 4th. Barclays reduced their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a research note on Monday, August 4th. Bank of America reduced their price objective on Bruker from $61.00 to $50.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Wells Fargo & Company reduced their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Tuesday, August 5th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Orbis Allan Gray Ltd purchased a new position in shares of Bruker during the second quarter valued at about $192,735,000. London Co. of Virginia grew its position in shares of Bruker by 78.4% during the fourth quarter. London Co. of Virginia now owns 4,193,454 shares of the medical research company's stock valued at $245,820,000 after purchasing an additional 1,843,294 shares in the last quarter. AQR Capital Management LLC grew its position in shares of Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company's stock valued at $137,065,000 after purchasing an additional 1,850,215 shares in the last quarter. Sculptor Capital LP lifted its position in Bruker by 18.3% during the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company's stock valued at $126,682,000 after purchasing an additional 476,363 shares during the last quarter. Finally, Brown Advisory Inc. grew its stake in shares of Bruker by 13.9% in the 2nd quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company's stock worth $113,142,000 after buying an additional 336,026 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Bruker Stock Performance

Shares of NASDAQ BRKR traded up $1.04 during midday trading on Thursday, hitting $30.83. 8,539,948 shares of the stock traded hands, compared to its average volume of 3,799,900. The firm has a 50-day moving average of $37.12 and a two-hundred day moving average of $39.68. The firm has a market capitalization of $4.68 billion, a P/E ratio of 59.29, a PEG ratio of 3.71 and a beta of 1.21. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker has a one year low of $28.53 and a one year high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The medical research company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $797.40 million for the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. Bruker's quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. On average, equities analysts forecast that Bruker will post 2.69 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Shareholders of record on Tuesday, September 23rd will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Tuesday, September 23rd. Bruker's dividend payout ratio is presently 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.